Alemtuzumab has been associated with the emergence of secondary autoimmune diseases. We report a case of a patient with relapsing-remitting multiple sclerosis who developed a refractory immune thrombocytopaenia associated with vasculitis, myelofibrosis and later Guillain-Barré syndrome following alemtuzumab. The medical community should be aware of unusual and unexpected adverse events that may be associated with alemtuzumab, especially when occurring simultaneously in the same patient.
Keywords: Biological agents; Multiple sclerosis; Neurology (drugs and medicines); Vasculitis.
© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.